While amylin holds promise as a therapeutic agent, its translation into clinical practice is hampered by complex receptor biology, the limitations of animal models, its amyloidogenic properties and pharmacokinetic challenges
Doktor tavsiyesi ile ylda 2 kez tekrarlanabilir
We thank Robert Bok, MD, PhD, Romelyn Delos Santos, MD, Caroline Guglielmetti, PhD, and Tony Huynh, Hsin-Yu Chen, PhD for their assistance with experiments and helpful discussion
Commonly Reported Side Effects Based on community reports, side effects appear relatively uncommon and typically mild: Most Frequently Reported: Injection site reactions (redness, minor pain, itching) Mild nausea (particularly with oral administration) Temporary dizziness Headache Fatigue Less Commonly Reported: Skin flushing Changes in appetite Temporary mood changes Vivid dreams Theoretical Concerns Growth Factor Effects: BPC-157's upregulation of growth factors raises theoretical concerns for: Cancer promotion in those with existing malignancies Acceleration of undiagnosed tumors Effects on benign growths (polyps, fibroids) No evidence directly supports these concerns, but caution is warranted given the mechanisms involved